AUTHOR=Xu Ling , Liu Yinhua , Fan Zhimin , Jiang Zefei , Liu Yunjiang , Ling Rui , Zhang Jianguo , Yu Zhigang , Jin Feng , Wang Chuan , Cui Shude , Wang Shu , Mao Dahua , Han Bing , Wang Tao , Zhang Geng , Wang Ting , Guo Baoliang , Yu Lixiang , Xu Yingying , Fu Fangmeng , Liu Zhenzhen , Wang Siyuan , Luo Ke , Xiang Qian , Zhang Zhuo , Liu Qianxin , Zhou Bin , Liu Zhaorui , Ma Chao , Tong Weiwei , Mao Jie , Duan Xuening , Cui Yimin 

TITLE=Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.606477

DOI=10.3389/fonc.2021.606477

ISSN=2234-943X

ABSTRACT=<p>This study was to assess the prognosis stratification of the clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease, the nuclear grade 3 tumor pathology (CPS + EG), Neo-Bioscore, and a modified Neo-Bioscore system in breast cancer patients after preoperative systemic therapy (PST). A retrospective multicenter cohort study was conducted from 12 participating hospitals’ databases from 2006 to 2015. Five-year disease free survival (DFS), disease specific survival (DSS), and overall survival (OS) were calculated using Kaplan–Meier Method. Area under the curve (AUC) of the three staging systems was compared. Wald test and maximum likelihood estimates in Cox proportional hazards model were used for multivariate analysis. A total of 1,077 patients were enrolled. The CPS + EG, Neo-Bioscore, and modified Neo-Bioscore could all stratify the DFS, DSS, and OS (all P &lt; 0.001). While in the same stratum of Neo-Bioscore scores 2 and 3, the HER2-positive patients without trastuzumab therapy had much poorer DSS (P = 0.013 and P values &lt; 0.01, respectively) as compared to HER2-positive patients with trastuzumab therapy and HER2-negative patients. Only the modified Neo-Bioscore had a significantly higher stratification of 5-year DSS than PS (AUC 0.79 <italic>vs</italic>. 0.65, P = 0.03). So, the modified Neo-Bioscore could circumvent the limitation of CPS + EG or Neo-Bioscore.</p><sec><title>Clinical Trial Registration</title><p><uri xlink:href="https://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</uri>, identifier NCT03437837.</p></sec>